Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SBC Medical Group Holdings (SBC) Cash & Equivalents (2022 - 2025)

SBC Medical Group Holdings filings provide 4 years of Cash & Equivalents readings, the most recent being $163.8 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 30.97% to $163.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $163.8 million, a 30.97% increase, with the full-year FY2025 number at $163.8 million, up 30.97% from a year prior.
  • Cash & Equivalents hit $163.8 million in Q4 2025 for SBC Medical Group Holdings, up from $127.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $163.8 million in Q4 2025 to a low of $217348.0 in Q1 2023.
  • Median Cash & Equivalents over the past 4 years was $114.0 million (2023), compared with a mean of $78.8 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 23822.07% in 2024 and later dropped 7.25% in 2025.
  • SBC Medical Group Holdings' Cash & Equivalents stood at $485564.0 in 2022, then skyrocketed by 21117.17% to $103.0 million in 2023, then grew by 21.38% to $125.0 million in 2024, then soared by 30.97% to $163.8 million in 2025.
  • The last three reported values for Cash & Equivalents were $163.8 million (Q4 2025), $127.4 million (Q3 2025), and $152.7 million (Q2 2025) per Business Quant data.